BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) Files An 8-K Results of Operations and Financial Condition

BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On August 10, 2017, BioLife Solutions, Inc. (the “Company”) issued a press release announcing the financial results and operational highlights for the second quarter ended June, 30 2017. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.
ExhibitNo. Description
99.1 Press release, dated August 10, 2017


BIOLIFE SOLUTIONS INC Exhibit
EX-99.1 2 v472868_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1         BioLife Solutions Announces Second Quarter 2017 Financial Results   29% Year Over Year Revenue Growth   Conference Call and Webcast Today at 4:30 PM Eastern Time   BOTHELL,…
To view the full exhibit click here

About BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS)

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

An ad to help with our costs